Travoprost ophthalmic solution, 0.004% (new formulation)

DRUG2 trials

Sponsors

Alcon Research

Conditions

GlaucomaOcular HypertensionOpen Angle Glaucoma

Phase 1

Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

CompletedNCT01658839

Alcon ResearchGlaucoma, Ocular Hypertension

Start: 2013-01-31End: 2013-07-31Updated: 2016-04-01

Phase 3

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

WithdrawnNCT01452009

Alcon ResearchOcular Hypertension, Open Angle Glaucoma

Start: 2011-11-30End: 2011-12-31Updated: 2012-02-10